672 related articles for article (PubMed ID: 11735645)
1. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones and liver toxicity.
Scheen AJ
Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
Parker JC
Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
7. Differentiating members of the thiazolidinedione class: a focus on safety.
Lebovitz HE
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
[TBL] [Abstract][Full Text] [Related]
8. [The development of thiazolidinedione drugs as anti-diabetic agents].
Kuzuya T
Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
10. [Thiazolidinediones: clinical data and perspectives].
Blicklé JF
Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
12. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Wagstaff AJ; Goa KL
Drugs; 2002; 62(12):1805-37. PubMed ID: 12149047
[TBL] [Abstract][Full Text] [Related]
14. Second-generation thiazolidinediones and hepatotoxicity.
Marcy TR; Britton ML; Blevins SM
Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
[TBL] [Abstract][Full Text] [Related]
15. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Gitlin N; Julie NL; Spurr CL; Lim KN; Juarbe HM
Ann Intern Med; 1998 Jul; 129(1):36-8. PubMed ID: 9652997
[No Abstract] [Full Text] [Related]
16. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
Gegick CG; Altheimer MD
Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
18. [Glitazones. Profile of a new class of substances].
Janka HU
Internist (Berl); 2001 Apr; 42(4):587-96. PubMed ID: 11326741
[No Abstract] [Full Text] [Related]
19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
20. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
